Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
Subscribe To Our Newsletter & Stay Updated